1 / 46

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus. DPP-4 Inhibitor CV Outcomes Trials in T2DM. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class. SAVOR-TIMI 53: Primary Endpoint. SAVOR-TIMI 53: Hospitalization for HF. EXAMINE: Primary Endpoint. EXAMINE: Hospitalization for HF.

ealy
Download Presentation

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

  2. DPP-4 Inhibitor CV Outcomes Trials in T2DM

  3. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class

  4. SAVOR-TIMI 53: Primary Endpoint

  5. SAVOR-TIMI 53: Hospitalization for HF

  6. EXAMINE: Primary Endpoint

  7. EXAMINE: Hospitalization for HF

  8. TECOS: Study Design

  9. TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

  10. TECOS: Hospitalization for HF

  11. DPP-4 Inhibitors: Hypoglycemia

  12. DPP-4 Inhibitors: Pancreatitis

  13. Future DPP-4 CV Outcomes Trials in T2DM

  14. Managing T2DM: incorporating injectable fixed-dose combinations

  15. Fixed-dose Combinations

  16. Why Combine Basal Insulin and GLP-1 RAs?

  17. DUAL-I: HbA1c Comparison

  18. DUAL-I: Percentage of Patients to Target HbA1c

  19. DUAL-I: Change in Body Weight

  20. DUAL-I: Confirmed Hypoglycemia

  21. DUAL-I: Nausea Over 26 Weeks

  22. Addition of Insulin to GLP-1 RA and Addition of GLP-1 RA to Insulin in T2DM

  23. When and How Should We Use Combination Therapies?

  24. T2DM, CV SAFETy, and efficacy: GLP-1 Receptor Agonists in focus

  25. ELIXA: Severe Symptomatic Hypoglycemia

  26. T2DM, CV SAFETy, and efficacy: SGLT2 Inhibitors in focus

  27. EMPA-REG OUTCOME

  28. EMPA-REG OUTCOME: Study Design

  29. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

  30. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

  31. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

  32. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-cause Mortality

  33. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

  34. Future SGLT2 Inhibitor CV Outcomes Trials

More Related